Portsmouth, Virginia 23708


Purpose:

Gastroesophageal reflux disease (GERD) is a common ailment affecting a significant portion of the US population. With the advent and increased use of esophageal impedance monitoring, both acid and nonacid reflux disease can be better diagnosed and treated. Patients with severe symptoms or symptoms refractory to medical management may be offered anti-reflux surgery for optimal treatment. Though there are a handful of studies evaluating the efficacy of anti-reflux surgery on those patients with acid or non-acid related reflux disease, the comparison between acid and non-acid reflux disease following surgery is lacking. We propose a prospective study comparing clinical outcomes from those patients with acid versus non-acid reflux disease following anti-reflux surgery with the use of validated and disease specific quality of life surveys.


Criteria:

Inclusion Criteria: - Patients who are offered anti-reflux surgical treatment with elevated DeMeester scores or with low (less than 14.7) DeMeester scores, but with positive impedance scores (positive symptom index associated with reflux episodes). Exclusion Criteria: - • Previous major upper gastrointestinal surgery (includes esophagus, stomach, and duodenum) - previous cholecystectomy (gallbladder removal) is not considered a major upper GI surgery - Presence of paraesophageal hernia (type II - type IV) - Presence of large hiatal hernia >5cm - Presence of peptic strictures - History of severe esophageal motility disorders such as: - achalasia - diffuse esophageal spasms - scleroderma - poorly-controlled diabetes mellitus - autonomic or peripheral neuropathy - myopathy - Pregnancy (As a standard operating procedure, women of child-bearing age will undergo a urine pregnancy test the morning of surgery because anti-reflux surgery is considered an elective case, where pregnancy is a relative contraindication.) - BMI greater than 40 - Undergoes Collis gastroplasty during surgery - Conversion to an open procedure - Age less than 18 years old


NCT ID:

NCT01241149


Primary Contact:

Principal Investigator
Ellie Mentler, MD
Naval Medical Center Portsmouth

Ellie Mentler, MD
Phone: 757-953-2454
Email: ellie.mentler@med.navy.mil


Backup Contact:

Email: charles.morgan@med.navy.mil
Charles Morgan, PhD
Phone: 757-953-5939


Location Contact:

Portsmouth, Virginia 23708
United States

Ellie Mentler, MD
Phone: 757-953-2454
Email: ellie.mentler@med.navy.mil

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.